Clinical application and efficacy analysis of partial cystectomy combined with intravesical chemotherapy in muscle-invasive bladder cancer

被引:0
|
作者
Zhang, Bin [1 ]
Liu, Tengfei [2 ]
He, Yang [1 ]
Han, Dali [1 ]
Qi, Peng [1 ]
Zheng, Duo [1 ]
Liu, Junyao [1 ]
Zhang, Xingxing [1 ]
Yue, Zhongjin [1 ]
Shang, Panfeng [1 ]
机构
[1] Lanzhou Univ, Gansu Nephrourol Clin Ctr, Key Lab Urol Dis Gansu Prov, Dept Urol,Inst Urol,Hosp 2, Lanzhou 730030, Gansu, Peoples R China
[2] Pingmei Shenma Grp, Dept Urol, Gen Hosp, Pingdingshan 467002, Henan, Peoples R China
关键词
Muscle-invasive bladder cancer; Partial cystectomy; Radical; OPEN RADICAL CYSTECTOMY; OUTCOMES;
D O I
10.1186/s12894-023-01267-w
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives Comparing the long-term tumor control results of partial cystectomy(PC)and radical cystectomy(RC)in the treatment of muscle-invasive bladder cancer, and to explore the feasible method of bladder preservation therapy (BPT)in patients with MIBC. Methods We retrospectively analyzed the clinical data of 102 patients with muscle-invasive bladder cancer in our hospital between January 2012 and December 2018, of whom 32 cases in the partial cystectomy group and 70 cases in the radical cystectomy group. We performed a comparative analysis of patient general information, perioperative-related indicators and postoperative follow-up data, comparing OS, PFS, and DSS at 1, 2, 3, 4, and 5 years in both groups, and comparing tumour recurrence and metastasis in postoperative patients. Results All the 102 cases in this study were successfully completed. Partial cystectomy group and Radical cystectomy group median operating time (169.50(130.00 similar to 225.25) min and 420.00(343.75 similar to 483.75) min, p < 0.001), median intraoperative blood loss was (100(50 similar to 100)ml and 400(200 similar to 1000)ml, p < 0.001), median perioperative blood transfusion volume (0(0 similar to 0)ml and 600(150.00 similar to 906.25)ml, p < 0.001), median total hospital stay (18(14.25 similar to 20.00) and 24.5(20.00 similar to 34.25) days, p < 0.001), median preoperative preparation time (7(4.25 similar to 8.00) and 10(8.00 similar to 13.00) days, p < 0.001), median postoperative hospital stay (9(8.00 similar to 13.50) and 14(11.00 similar to 21.25) days, p < 0.001), the incidence of perioperative blood transfusion was (15.6% and 75.7%, p < 0.001), the incidence of surgical complications was(28.1%(9/32) and 50.0%(35/70), p = 0.033), average hospitalization cost ((26435.76 +/- 9877.82) yuan and (58464.36 +/- 19753.13) yuan, p < 0.001), the differences were statistically significant (p < 0.05). Perioperative mortality (0 vs. 2.9%(2/70), p = 1), and OS at 1, 2, 3, 4, and 5 years after surgery were (80.0%, 59.8%, 56.1%, 51.0%, 44.6% vs. 76.5%, 67.4%, 64.9%, 57.9%, 52.6%, p = 0.524), PFS (68.2%, 64.6%, 60.3%, 54.8%, 54.8% vs. 82.7%, 78.3%, 75.4%, 67.3%, 62.1%, p = 0.259). DSS (89.9%, 72.4%, 68.6%, 68.6%, 62.4% vs. 87.3%, 83.4%, 80.9%, 73.6%, 68.0%, p = 0.424), and the incidence of tumor recurrence or metastasis was (40.0%(12/30) vs. 25.4%(16/63), p = 0.151), the differences were not statistically significant (p > 0.05). Conclusion In patients with limited solitary T2N0M0 and T3N0M0 muscle-invasive bladder cancer, partial cystectomy plus bladder instillations treatment can achieve comparable tumour control to radical cystectomy. However, patients in the PC group have significant advantages in terms of operative time, intraoperative bleeding, intraoperative and postoperative blood transfusion, preoperative preparation time, total hospital stay, postoperative recovery time, operative costs and operative complications. This option may be considered for such patients with a need for bladder preservation.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Retrospective Analysis of the Efficacy of Two Cycles of M-VAC Neoadjuvant Chemotherapy Followed by Radical Cystectomy for Muscle-invasive Bladder Cancer
    Kitagawa, Yasuhide
    Izumi, Komi
    Miwa, Sotaro
    Kadono, Yoshifumi
    Konaka, Hiroyuki
    Mizokami, Atsushi
    Namiki, Mikio
    [J]. ANTICANCER RESEARCH, 2013, 33 (10) : 4497 - 4503
  • [32] Analysis of Intravesical Recurrence After Bladder-preserving Therapy for Muscle-invasive Bladder Cancer
    Onozawa, Mizuki
    Miyanaga, Naoto
    Hinotsu, Shiro
    Miyazaki, Jun
    Oikawa, Takehiro
    Kimura, Tomokazu
    Takaoka, Ei-ichiro
    Kawai, Koji
    Shimazui, Toru
    Sakurai, Hideyuki
    Nishiyama, Hiroyuki
    Akaza, Hideyuki
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 42 (09) : 825 - 830
  • [33] SEX DIFFERENCES IN MUSCLE-INVASIVE BLADDER CANCER WITH RADICAL CYSTECTOMY
    Liblik, Kiera
    Whitehead, Marlo
    Siemens, Robert
    [J]. JOURNAL OF UROLOGY, 2024, 211 (05): : E342 - E343
  • [34] Radical Cystectomy and the Multidisciplinary Management of Muscle-Invasive Bladder Cancer
    Chedgy, Edmund Charles Paul
    Black, Peter C.
    [J]. JAMA ONCOLOGY, 2016, 2 (07) : 855 - 856
  • [35] Neoadjuvant chemotherapy or cystectomy for muscle-invasive bladder cancer - an analysis of survival outcomes at a UK tertiary referral centre
    Veeratterapillay, R.
    Sultan, N.
    Vasdev, N.
    Pedley, I.
    Frew, J.
    Paez, E.
    Johnson, M. I.
    Thorpe, A. C.
    [J]. BJU INTERNATIONAL, 2013, 111 : 70 - 70
  • [36] Safety and efficacy of preoperative chemotherapy for muscle-invasive bladder cancer in elderly patients
    Dumont, Clement
    Aregui, Amelie
    Hauchecorne, Mathilde
    Lefevre, Madeleine
    Aussedat, Quiterie
    Reignier, Pierre-Louis
    Gauthier, Helene
    Hennequin, Christophe
    Fossey-Diaz, Virginie
    Xylinas, Evanguelos
    Pachev, Atanas
    Desgrandchamps, Francois
    Masson-Lecomte, Alexandra
    Culine, Stephane
    [J]. WORLD JOURNAL OF UROLOGY, 2023, 41 (10) : 2715 - 2722
  • [37] THE EFFICACY OF GC VERSUS MVAC CHEMOTHERAPY REGIMEN FOR MUSCLE-INVASIVE BLADDER CANCER
    Liu, Liwei
    Liu, Chunyu
    [J]. INTERNATIONAL JOURNAL OF UROLOGY, 2014, 21 : A214 - A214
  • [38] Feasibility and efficacy of gemcitabine and carboplatin neoadjuvant chemotherapy in muscle-invasive bladder cancer
    Koie, T.
    Yamamoto, H.
    Okamoto, A.
    Hatakeyama, S.
    Momose, A.
    Iwabuchi, I.
    Yoneyama, T.
    Hashimoto, Y.
    Kamimura, N.
    Ohyama, C.
    Saijo, Y.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [39] Safety and efficacy of preoperative chemotherapy for muscle-invasive bladder cancer in elderly patients
    Clément Dumont
    Amélie Aregui
    Mathilde Hauchecorne
    Madeleine Lefèvre
    Quiterie Aussedat
    Pierre-Louis Reignier
    Hélène Gauthier
    Christophe Hennequin
    Virginie Fossey-Diaz
    Evanguelos Xylinas
    Atanas Pachev
    François Desgrandchamps
    Alexandra Masson-Lecomte
    Stéphane Culine
    [J]. World Journal of Urology, 2023, 41 : 2715 - 2722
  • [40] A single-center experience of chemotherapy for muscle-invasive bladder cancer after radical cystectomy
    Kotowski, Adam S.
    Stegemann, Andrew
    Rehman, Shabnam
    Attwood, Kristopher
    Levine, Ellis Glenn
    Guru, Khurshid
    Trump, Donald L.
    Pili, Roberto
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)